3 Cano Health board members resign, vow to oust CEO

The latest stories trending on MedCity News.

Editor's Pick

Top Story 3 Cano Health Board Members Resign & Vow to Oust CEO Amid 'Decimated' Stock Price Three of Cano Health's board members recently resigned in protest of the company's management strategy and announced they will form a group to enact comprehensive changes at Cano, including replacing the CEO. They said Cano's governance structure has caused the company's stock price "to be decimated, dropping over 90% from its debut" and has saddled the firm with a "crippling debt burden." Sponsored Content The Vibe at Vive: A Progress Report on Healthcare Transformation Presented by Integra Connect and MedCity News Hear from healthcare executives such as COO Cory Wiegert of Integra Connect on how they are meeting the challenges of healthcare innovation. Watch it here Here's Why You Should Attend INVEST 2023 "I often find the more targeted industry events provide an environment very conducive to connecting with others. MedCity INVEST definitely falls in that category for me. My most recent angel investment came through a contact first made (and subsequent relationship developed) at the INVEST conference. A big thank you to the MedCity team!" ~ G. Winokur, Angel Investor Early Bird Savings of $400 Ends Friday - Register Now!

Featured News

Why Sofinnova is Betting on the Confluence of Digital Technology and the Life Sciences Paris-based Sofinnova Partners announced last week that it has launched a new strategy aimed at investing in a new breed of startups that straddle the lines between data and biology. Zócalo Health Teams Up with Mark Cuban's Pharmacy to Increase Medication Access for Latino Patients Zócalo Health, a virtual primary care provider designed for Latino patients, recently forged a collaboration with Mark Cuban's Cost Plus Drugs. Now all Zócalo patients have access to Cost Plus Drugs' prescriptions, and the provider's community health workers have been trained to help walk patients through the process of obtaining medications through the pharmacy. Bio Startup Scorpion Partners With Pierre Fabre for Trials of Targeted Lung Cancer Drugs Pierre Fabre is paying Scorpion Therapeutics $65 million to begin a partnership on clinical development and potential commercialization of two targeted therapies for non-small cell lung cancer. The Scorpion drugs could have safety advantages over approved Johnson & Johnson and Takeda therapies that address the same rare genetic signature. The Promise of Healthcare Pricing Transparency: As Costs Rise, More Custom Solutions May Help Meet Demand It's not enough to be hopeful that hospitals with the right tools—and incentives will put prices out there on a menu for all to see. Luckily, for employers and employees who want to access affordable healthcare, new and emerging solutions are empowering them with information and options. Advocates of Digital Therapies Hope Bill Can Ease Reimbursement A similar bill appeared last year but did not progress. Given the potential costs of reimbursing prescription digital therapeutics, Congress could be skeptical. Still, with growing attention on mental health, advocates are optimistic. Patient Deaths and Partial Hold Prompt Gossamer Bio to Stop Work on Cancer Drug Two fatalities were reported in an early-stage study testing a Gossamer Bio drug intended to treat a rare cancer affecting the central nervous system. Due to the adverse events and a partial FDA clinical hold, Gossamer has decided to stop work on the program.

Resources

MedCity Moves Podcast: Recent Hires and Layoffs In this month's episode, we dive into some of the recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Tom Richards, who recently became the new executive vice president of business development at Transcarent after spending more than 35 years at Cigna. Listen Now

MedCity News • 611 Broadway • New York, NY unsubscribe